Article
An orally bioavailable tyrosine kinase inhibitor demonstrated dramatic and rapid effects on advanced prostate cancer, according to researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.